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Loading After Seeing*Borja Ibáñez, MD, PHD,yz George Dangas, MD, PHDxA n early invasive strategy has become thestandard of care for patients with non–ST-segment elevation myocardial infarction
(NSTEMI) (1,2). Atherosclerotic plaque disruption/
erosion with superimposed thrombus is the underly-
ing etiology of most cases of NSTEMI. Consequently,
many patients with NSTEMI undergo percutaneous
coronary intervention (PCI) and are treated with
coronary stenting during the index catheterization
procedure. Approximately one-third of patients are
typically triaged after diagnostic angiography to
cardiac procedure or treated medically. Besides early
catheterization, anticoagulant/antiplatelet therapies
represent the cornerstone of pharmacological strat-
egy for NSTEMI. The role of dual antiplatelet therapy
(aspirin plus a P2Y12 inhibitor) has been shown to be
critical not only as immediate treatment of the
NSTEMI episode but also as maintenance therapy to
prevent stent thrombosis and major adverse cardio-
vascular events in the long term.
Thus, it is rather remarkable that the best timing for
the initiation of P2Y12 inhibitors in patients with
NSTEMI has not been clearly established. Clinical
guidelines (the 2012 American College of Cardiology
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guidelines) recommend the initiation of P2Y12 in-
hibitors “on presentation; as soon as possible” (i.e.,
before catheterization) (1,2) on the basis of clinical
evidence showing that “on admission” initiation of
P2Y12 inhibitors with clopidogrel was superior to no
administration of P2Y12 inhibitors (3,4). This appeared
to be a reasonable expert consensus given the delayed
onset of peak antiplatelet activity with the loading
dose of clopidogrel. Until the publication of the
ACCOAST (A Comparison of prasugrel at the time of
percutaneous Coronary intervention Or as pre-treat-
ment At the time of diagnosis in patients with non—ST-
segment elevation myocardial infarction) trial (5), no
study had ever compared different timings of P2Y12
initiation in patients with NSTEMI, making it a land-
mark trial. The ACCOAST trial randomized 4,033 pa-
tients with NSTEMI to pre-treatment with prasugrel (a
loading dose of prasugrel 2 to 48 h before catheteriza-
tion) or no pre-treatment with prasugrel (a loading
dose of prasugrel after initial angiography). The pri-
mary endpoint (composite of cardiovascular death,
myocardial infarction, stroke, urgent revasculariza-
tion, or glycoprotein IIb/IIIa inhibitor bailout through
day 7) was not different between groups. This result
implied that a similar clinical effect with a fast-acting
agent (onset within 30 min) can be achieved even if it
is given after deﬁnition of the coronary anatomy when
planning for PCI, thus avoiding unnecessary treatment
with this agent for patients suitable for cardiac sur-
gery procedure or medical therapy alone. The rate of
bleeding events (both coronary artery bypass graft
[CABG] related and non-CABG related) at 7 and 30 days
was signiﬁcantly higher in the prasugrel pre-treatment
group than in the no prasugrel pre-treatment group.SEE PAGE 2563In this issue of the Journal, Montalescot et al. (6)
present the results of analysis of the large subset
(69%) of subjects in the ACCOAST trial who
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2573underwent PCI. Concordant to the main study popu-
lation, the incidence of the primary (ischemia-
related) endpoint was identical (13.1%) between
groups. Also, as in the overall population, the rate of
all bleeding events was signiﬁcantly higher in the
prasugrel pre-treatment group than in the no prasu-
grel pre-treatment group.
Performing subgroup analyses of patients under-
going PCI in large NSTEMI trial populations has
limitations. First, the PCI population was not ran-
domized; thus, any potential unknown confounders
may affect the results. Second, the composition of
this subgroup is most probably affected by the study
intervention. Finally, the PCI subgroup is not a clin-
ically deﬁnable cohort (deﬁned after angiography,
and thus pre-PCI treatment is impossible to deﬁne).
Despite these limitations, the analysis of a subpopu-
lation undergoing PCI is of great value because it
represents the best case scenario favoring the study
drug/intervention in the mode of pre-treatment.
Pre-treatment with prasugrel was supposed to result
in higher platelet inhibition at the time of PCI and
thus was supposed to reduce ischemic complications
upon intervention. Against this reasonable assump-
tion was the ability of prasugrel itself to quickly
amass platelet inhibition even after coronary angi-
ography. In other words, would pre-treatment with
prasugrel (a few hours before the procedure) prevail
over its own virtue of fast-acting, high-intensity an-
tiplatelet action after coronary angiography? The
current study of patients who had PCI deﬁnitively
shows that pre-treatment with prasugrel is not
needed in patients with NSTEMI.
Of more concern is the signiﬁcant increase in
bleeding events in the prasugrel pre-treatment group,
although the incidence of major bleeding was low
(1.4% and 0.5% in the pre-treatment and no pre-
treatment groups, respectively). Almost 40% of all
major bleeding events in the prasugrel pre-treatment
group occurred at the vascular access site, which is
why it is remarkable that 43% of patients underwent
radial access. Of the 19 major bleeding events in the
prasugrel pre-treatment group, only 4 occurred in
patients undergoing radial access, similar to what was
observed in the no prasugrel pre-treatment group (of
all 7 major bleeding events, only one occurred in a
patient undergoing radial access). These data support
the superiority of choosing this arterial site in pre-
venting bleeding complications at the access site (7).
The higher bleeding rates in the prasugrel pre-
treatment group are not completely understood. It
could be hypothesized that pre-treatment with pra-
sugrel results in higher platelet inhibition at the time
of vascular access and that this translates into anincreased incidence of acute bleeding events. How-
ever, there is an unexplained increase in bleeding
events in the prasugrel pre-treatment group at
30 days. Of note, between day 7 and day 30, there
were 5 new major bleeding events in the prasugrel
pre-treatment group compared with 2 new major
bleeding events in no prasugrel pre-treatment group.
Given the rapid onset of the antiplatelet effect of
prasugrel, any excess bleeding a few hours after PCI is
unexpected. Finally, higher rates of bleeding com-
plications (mostly at the arterial access site) also were
observed in other studies of pre-treatment with
intense antiplatelet agents (8,9) as compared with
selective administration immediately before PCI.
How do these results apply to the wider spectrum
of acute coronary syndromes and to other clinically
recommended P2Y12 inhibitors? The results of the
ATLANTIC (A 30 Day Study to Evaluate Efﬁcacy and
Safety of Pre-hospital vs. In-hospital Initiation of
Ticagrelor Therapy in STEMI Patients Planned for
Percutaneous Coronary Intervention [PCI]) trial of
ticagrelor were very recently reported (10). This agent
is also able to produce a more potent and faster-onset
platelet P2Y12 inhibition than clopidogrel. More than
1,800 patients with ST-segment elevation myocardial
infarction were randomized to receive ticagrelor
during ambulance transfer or at the time of PCI. Pre-
treatment with ticagrelor was not associated with
better surrogates of perfusion (ST-segment resolu-
tion/Thrombolysis In Myocardial Infarction [TIMI]
ﬂow) and, importantly, was not associated with any
excess bleeding. Interestingly, the rate of acute stent
thrombosis was numerically lower in the ticagrelor
pre-treatment group, leaving room for further ex-
plorations regarding the role of pre-treatment with
ticagrelor in patients with ST-segment elevation
myocardial infarction.
The extrapolation of the results of the ACCOAST-PCI
study to all P2Y12 inhibitors in the context of NSTEMI
requires caution. The peak of antiplatelet action of
different P2Y12 inhibitors is a critical aspect; new
potent P2Y12 inhibitors (ticagrelor and prasugrel) have
a rapid antiplatelet effect. Conversely, clopidogrel
has a less rapid onset of action, and (the lower) peak
of antiplatelet activity is reached 4 to 6 h after
administration of the loading dose. In this regard, in-
direct analyses from the CREDO (Clopidogrel for the
Reduction of Events During Observation) trial (11)
suggested that the initiation of treatment with clopi-
dogrel several hours before PCI resulted in a reduction
of clinical events. These data show that the pre-
treatment strategy depends on the P2Y12 inhibitor
used. If this is clopidogrel, it seems reasonable to
adopt a pre-treatment strategy hours before
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2574angiography; if potent, fast-acting P2Y12 inhibition
with prasugrel is chosen, a no pre-treatment strategy
seems to be a better option. The latter strategy has the
beneﬁt of identifying candidates for CABG who would
not be treated with P2Y12 inhibitors and could there-
fore undergo surgery without delay. It also eliminates
unnecessary treatment of patients directed to any
type of surgery or medical therapy alone, thus afford-
ing fewer adverse effects for such patients.
What are the clinical implications of the ACCOAST
trial? The recent 2014 American Heart Association/
American College of Cardiology guidelines on NSTEMI
(12) have been reinforced by the data from the
ACCOAST trial. In these new guidelines, prasugrel is
not recommended for pre-treatment in patients with
NSTEMI, mostly on the basis of the ACCOAST trial. The
new guidelines recommend either clopidogrel or
ticagrelor in addition to aspirin (class I indication),
with no description of timing of initiation. In patientswho undergo an early invasive strategy, ticagrelor is
the preferred option (Class IIa indication). The Euro-
pean Society of Cardiology guidelines recommend
ticagrelor as the pre-treatment P2Y12 or clopidogrel in
patients who cannot be treated with ticagrelor. Similar
to the American Heart Association/American College
of Cardiology guidelines, prasugrel is recommended
only after angiography (2). Given that prasugrel is not
recommended as pre-treatment in both the American
and European NSTEMI guidelines, these trial results
are not expected to change clinical practice but
conﬁrm the robust evidence that is required to rein-
force society-driven clinical practice guidelines.
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